Ranbaxy's generic Nexium exclusivity: dead or alive?
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories and its acquirer Sun Pharmaceutical Industries were among the key losers on Indian bourses in early trade on 7 November after the FDA revoked previously granted tentative approvals for Ranbaxy’s ANDAs for generic versions of AstraZeneca's Nexium (esomeprazole magnesium) and Roche's Valcyte (valganciclovir hydrochloride).